BNN Breaking has published the news that LTR Pharma has initiated enrolment of patients for its pivotal bioequivalence clinical trial of the nasal spray treatment, SPONTAN®.
An excerpt:
“The implications of SPONTAN®’s success extend far beyond the realm of erectile dysfunction. A positive outcome from the trial could set the stage for regulatory approval from heavyweights like the FDA and TGA, marking a pivotal shift in how ED is treated globally.”